Table 3.
Potential medications that target oxidative stress in patients after hemorrhagic stroke.
| Drug name | Clinical trials | Different types of intracerebral hemorrhage | Action mechanism | Outcome | References |
|---|---|---|---|---|---|
| NXY-059 | NCT00075959 (CHANT) | ICH | Free radical-trapping agent | No benefit | [176] |
|
| |||||
| Deferoxamine mesylate | NCT01662895 (Hi-Def) | ICH | Iron-chelator | Phase II clinical trial | [177] |
|
| |||||
| Hydrogen-rich fluid | UMIN000014696 | SAH | Delayed cerebral ischemia and cerebral vasospasm | Ongoing | [160] |
|
| |||||
| Edaravone | — | SAH | Free radical scavenger | Preliminary | [178] |
|
| |||||
| Simvastatin |
NCT01077206
ISRCTN75948817 |
SAH | Lipid-lowering therapy | No benefit | [179, 180] |
|
| |||||
| Lipid-lowering medication | NCT00226096 and NCT00716079 (INTERACT) | ICH | Lipid-lowering therapy | No benefit | [181] |
|
| |||||
| Statin | NCT00221104 | SAH | Lipid-lowering therapy | No benefit | [182] |
ICH, intracranial hemorrhage; SAH, subarachnoid hemorrhage.